What Soufrane Treats: Main Uses and Benefits

The primary therapeutic domain of Soufrane is the local adjunctive treatment of nasopharyngeal mucosal disorders. It is commonly used across conditions presenting with acute or episodic changes, particularly in the context of the common cold and nasopharyngitis. The medication is relevant for managing symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort and functional strain associated with nasal obstruction and runny nose.

---

Supportive Symptomatic Relief

Soufrane is applied across domains where additional symptomatic support is needed, addressing symptoms related to localized inflammatory or irritative states. It is typically relevant for easing the discomfort and strain accompanying conditions like the common cold, uncomplicated nasopharyngitis, and temporary mucosal irritation. This supportive therapeutic benefit contributes to easing discomfort during periods of heightened symptoms in both adults and children over 30 months.

“It is commonly used when short-term symptomatic assistance is needed for localized discomfort.”

The medication provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when the mucosal manifestations become more noticeable.

Quick Fact: Support for Localized Discomfort
Soufrane is applied in addressing conditions where functional stability becomes affected by irritation, applied in addressing symptoms related to localized inflammatory or irritative states.

Regulatory References

1. Haute Autorité de Santé (HAS) in France

Eligibility for Soufrane: Official Regulatory Information

The eligibility profile for Soufrane (Tenoic Acid nasal spray) is strictly defined by regulatory documents, outlining populations permitted for use, those restricted due to lack of data, and individuals who are absolutely excluded.

Populations Excluded from Use

Classification	Population Rule (Contraindication)
Absolute Prohibition	Patients with known hypersensitivity (allergy) to the active substance, Tenoic Acid, or to any of the product’s components, including parabens (preservatives).

Populations with Restricted or Conditional Use

Official labeling does not recommend use during specific physiological states:

• Pregnancy: Use should be avoided as a precautionary measure due to insufficient clinical follow-up data to exclude potential risks.
• Lactation (Breastfeeding): Use should be avoided due to a lack of data regarding whether the drug passes into breast milk.

Age-Related Eligibility and Established Use

Soufrane is officially permitted for use across a wide age range, with established categories for:

• Adults
• Children over 30 months of age
• Infants

No specific restrictions or contraindications regarding eligibility are documented for patients with hepatic impairment (liver function) or renal impairment (kidney function).

The official interaction profile for Soufrane, which contains the active ingredient Tenoic Acid (Ethanolamine Salt) as a local nasal spray, is primarily defined by the absence of documented systemic interactions.

Documented Interaction Patterns

Category	Official Regulatory Documentation Statement
Interacting Product Categories	Other locally applied antiseptic solutions or products for the nasal or pharyngeal mucosa.
Mechanistic Basis of Interaction	Pharmacodynamic interference and/or additive local effect within the nasal cavity. No systemic pharmacokinetic mechanisms (e.g., CYP enzymes or transporters) are officially documented.
Timing-Based Rules	None documented. Official government labeling does not specify mandatory separation times from other medications.

Formal Restrictions and Classifications

There are no systemic medicinal products officially listed as contraindicated for co-administration in the regulatory labeling for this formulation of Tenoic Acid. This is consistent with its non-systemic, localized route of administration, which results in minimal systemic absorption.

Regulatory documents do not contain mandatory warnings about interactions with food, alcohol, herbal products, or supplements. The only official caution relates to the potential for local co-administration with other nasal antiseptics to alter the intended local effect of either agent. The profile is characterized by an overall absence of systemic drug-drug interactions as defined by regulatory agencies.

Pharmacodynamic Mechanism: Localized Mucosal Action

Soufrane's mechanism is defined by two primary actions localized to the nasal and upper respiratory mucosa. The compound, a thiophene carboxylate derivative, engages in the direct inhibition of proliferation of certain microorganisms, including local bacteria and fungi, by interfering with their structural integrity or essential metabolic pathways on the mucosal surface. This localized action modifies the biochemical environment of the nasal passage.

Separately, the compound's structure allows it to modulate specific cellular signaling pathways within the mucosal tissue, such as those governed by enzymes like COX or LOX. This interaction alters the output of local physiological mediators involved in the tissue's response to challenge. By modulating these cellular processes, the drug supports the stability and regulated responsiveness of the mucosal tissue without inducing systemic effects.

The medicine referred to as Soufrane is typically administered as Desflurane (SUPRANE®), a general inhalation anesthetic. Established requirements govern its use. It is administered strictly in a controlled medical setting by or under the direct supervision of persons trained in the administration of general anesthesia.

Official Administration Guidelines

Usage Constraint	Instruction from Regulatory Documents
Route & Delivery	Administered only by inhalation via a vaporizer specifically designed and designated for Desflurane.
Adult Dosing	Anesthesia maintenance concentrations typically range from 2.5%-8.5% in oxygen or oxygen/nitrous oxide mixtures.
Pediatric Use	Not approved for use as an inhalation agent for the induction of anesthesia in children and infants due to risks of respiratory adverse events. It is indicated for maintenance only in intubated pediatric patients.
Dose Adjustment	The Minimum Alveolar Concentration (MAC), which determines the required dose, decreases with increasing patient age and must be adjusted accordingly for geriatric patients.
Preparation	Administration requires the immediate availability of equipment for maintaining a patent airway and circulatory resuscitation. Desiccated carbon dioxide (CO2) absorbents must be replaced prior to use.
Frequency	The concentration is administered continuously for the duration of the surgical procedure and is individualized based on the patient's immediate response.

These official instructions define the required environment, specialized equipment, and concentration-based dosing necessary for the medicine's safe use. The protocol mandates continuous monitoring and strictly prohibits inhalation induction in pediatric populations, establishing a highly controlled procedural framework.

Research Evidence: Overview of Studies

Early Research Findings

Research investigated how the drug interacts with the body. Preclinical studies explored whether this mechanism could alter disease progression models.

Initial pharmacokinetic studies examined the drug’s absorption, distribution, metabolism, and excretion in healthy volunteers. Early trials reported changes in assessed clinical parameters, though further investigation is needed.

Phase 2 and 3 Clinical Trials

Clinical Parameters and Symptom Scores

Studies investigated the effect of the drug on inflammation markers and disease activity scores over a 12-week period.

• One Phase 2 trial evaluated various dosing schedules; the study’s primary endpoint was an assessment of symptom severity changes.
• One Phase 3 study found a difference in outcomes between the drug and placebo across the primary endpoint. This study reported data on participants across multiple international sites.

Combination Therapy

Studies examined the combination of the drug and standard therapy, and reported a difference in symptom scores, relative to standard therapy alone. The researchers examined whether the drug's co-administration influenced the tolerability profile of the standard therapy.

Patient-Reported Outcomes

Studies investigated the drug’s association with pain. They assessed patient-reported outcomes, including several quality of life indices. Some studies reported a short timeframe for observing initial changes in pain scores.

Safety, Tolerability, and Special Populations

Adverse Events

Clinical trials cataloged the frequency of common adverse events, which primarily included mild headache and fatigue. The data indicated that the withdrawal rate due to adverse events was similar between the drug group and the placebo group.

Long-Term Follow-Up

Studies assessed the long-term administration of the drug in adults over a period of two years. Researchers monitored the incidence of rare and serious adverse events during this extension phase.

Renal and Hepatic Impairment

Research included an evaluation of the treatment in participants with liver impairment. The pharmacokinetics of the drug were evaluated in individuals with varying degrees of renal impairment to determine whether dose adjustments were needed.

Key Studies & References

1. Ondansetron - StatPearls - NCBI Bookshelf (Pharmacokinetics, Mechanism of Action, Adverse Effects)
2. Ondansetron metabolism and pharmacokinetics (Review of Clearance and Half-life in special populations)

Common questions about Soufrane (FAQ)

Q: Is Soufrane a controlled substance?

According to the official classification, Soufrane is described as an Antiseptic and Nasal Adjuvant Decongestant intended for local use. Regulatory documents characterize the medicine's action as localized within the nasal cavity, which is consistent with minimal systemic absorption. Consistent with this classification, official government agencies do not classify the medicine as a controlled substance.

Q: Are there different strengths or versions of Soufrane?

Official product information for Soufrane describes the medicine as a specific Aqueous Nasal Spray Solution containing the active ingredient Tenoic Acid (Ethananolamine Salt). The product is formulated as an aqueous nasal spray, designed for local delivery to the nasal lining. Official regulatory documents define a single formulation for this product, and no alternative strengths or versions are currently specified.

How to Store and Dispose of Soufrane

The storage and disposal requirements for Soufrane (Tenoic Acid Nasal Spray) are defined by regulatory labeling to maintain the product's integrity and safety.

Storage Conditions

• Temperature and Protection: The medicine must be stored at controlled room temperature and must not be frozen.
• Packaging: Store the product in its original container and ensure it is kept tightly closed when not in use.
• Child Safety: Soufrane must be stored out of the sight and reach of children.

Stability and Disposal

Regulatory documents caution against prolonged use after the first opening due to the labeled risk of microbial contamination. Unused or expired medication must be disposed of according to local regulations for pharmaceutical waste. The product should not be discarded into wastewater systems.